Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford University, Stanford, California, USA.
Department of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, Atlanta, Georgia, USA.
J Clin Invest. 2023 May 15;133(10):e167955. doi: 10.1172/JCI167955.
BackgroundMaintaining durable immunity following vaccination represents a major challenge, but whether mRNA booster vaccination improves durability is unknown.MethodsWe measured antibody responses in 55 healthy adults, who received a booster dose of the Pfizer-BioNTech or Moderna vaccine against SARS-CoV-2 and calculated the half-life of the antibody titers. We also measured memory B and T cell responses in a subset of 28 participants. In 13 volunteers who received a second booster vaccine, we measured serum antibody titers and memory B and T cell responses.ResultsThe booster (third immunization) dose at 6 to 10 months increased the half-life of the serum-neutralizing antibody (nAb) titers to 76 days from 56 to 66 days after the primary 2-dose vaccination. A second booster dose (fourth immunization) a year after the primary vaccination further increased the half-life to 88 days. However, despite this modestly improved durability in nAb responses against the ancestral (WA.1) strain, there was a loss of neutralization capacity against the Omicron subvariants BA.2.75.2, BQ.1.1, and XBB.1.5 (48-, 71-, and 66-fold drop in titers, respectively, relative to the WA.1 strain). Although only 45% to 65% of participants demonstrated a detectable nAb titer against the newer variants after the booster (third dose), the response declined to below the detection limit in almost all individuals by 6 months. In contrast, booster vaccination induced antigen-specific memory B and T cells that persisted for at least 6 months.ConclusionThe durability of serum antibody responses improves only marginally following booster immunizations with the Pfizer-BioNTech or Moderna mRNA vaccines.
背景:在接种疫苗后保持持久的免疫力是一项重大挑战,但 mRNA 加强针接种是否能提高持久性尚不清楚。
方法:我们测量了 55 名健康成年人接种辉瑞-生物科技或 Moderna 公司的 SARS-CoV-2 疫苗加强针后的抗体反应,并计算了抗体滴度的半衰期。我们还在 28 名参与者中测量了记忆 B 和 T 细胞反应。在 13 名接受第二次加强疫苗的志愿者中,我们测量了血清抗体滴度和记忆 B 和 T 细胞反应。
结果:在 6 至 10 个月时,加强针(第三次接种)将血清中和抗体(nAb)滴度的半衰期从两剂疫苗接种后 56 天延长至 76 天。在初次接种一年后进行第二次加强针(第四次接种)进一步将半衰期延长至 88 天。然而,尽管 nAb 对原始(WA.1)株的反应持久性略有提高,但对奥密克戎亚变体 BA.2.75.2、BQ.1.1 和 XBB.1.5 的中和能力丧失。与 WA.1 株相比,nAb 滴度分别下降了 48、71 和 66 倍。尽管在加强针(第三剂)后只有 45%至 65%的参与者对新变体有可检测到的 nAb 滴度,但在几乎所有个体中,反应在 6 个月内下降到检测限以下。相比之下,加强针接种诱导了抗原特异性记忆 B 和 T 细胞,这些细胞至少持续了 6 个月。
结论:辉瑞-生物科技或 Moderna mRNA 疫苗加强针接种后,血清抗体反应的持久性仅略有提高。
J Clin Invest. 2023-5-15
Vaccines (Basel). 2025-7-28
Nat Microbiol. 2025-8
Commun Med (Lond). 2025-6-20
Vaccines (Basel). 2025-3-12
N Engl J Med. 2023-1-12
Cell Host Microbe. 2023-1-11
Ann Allergy Asthma Immunol. 2023-1
N Engl J Med. 2022-9-29
N Engl J Med. 2022-10-6